Pharmacokinetic–pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature

In acute and chronic pain, the objective of pharmacokinetic–pharmacodynamic (PKPD) modeling is the development and application of mathematical models to describe and/or predict the time course of the pharmacokinetics (PK) and pharmacodynamics (PD) of analgesic agents and link PK to PD. Performing population PKPD modeling using nonlinear mixed effects modeling allows, apart from the estimation of fixed effects (the PK and PD model estimates), the quantification of random effects as within- and between-subject variability. Effect-compartment models and mechanism-based biophase distribution models that incorporate drug-association and -dissociation kinetics are applied in PKPD modeling of pain treatment. Mechanism-based models enable the quantification of the rate-limiting factors in drug effect owing to drug distribution versus receptor kinetics (since receptor kinetics are nonlinear they are discernable from the linear effect-compartment kinetics). It is a helpful technique in understanding the complex behavior of specific analgesics, such as buprenorphine, but also morphine and its active metabolite morphine-6-glucuronide, especially with respect to the reversal of opioid-induced side effects, most importantly life-threatening respiratory depression. One approach in chronic pain studies is the application of mixture models. Mixture models do not necessarily need to take PK data into account and allow the objective differentiation of measured responses to analgesics into specific response subgroups, and as such, may play an important role in analyzing Phase I and II analgesia studies. Appropriate application of PKPD modeling leads to the improvement of current therapeutics with respect to dose design and outcome, understanding the interaction of analgesics within complex chronic pain disease processes and may play an important role in drug development. In the current article, novel observations using the aforementioned techniques on opioids, NSAIDs, epidural analgesia, ketamine and GABA-ergic drugs in acute and chronic pain are discussed.

[1]  G. Segre,et al.  Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.

[2]  C J Hull,et al.  Pharmacokinetics and pharmacodynamics. , 1979, British journal of anaesthesia.

[3]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[4]  L Aarons,et al.  Population pharmacokinetics. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[5]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[6]  N. Holford,et al.  Perioperative pharmacodynamics of acetaminophen analgesia in children. , 1999, Anesthesiology.

[7]  A. Dahan,et al.  Sex Differences in Morphine Analgesia: An Experimental Study in Healthy Volunteers , 2000, Anesthesiology.

[8]  A. Dahan,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Morphine-6-glucuronide-induced Analgesia in Healthy Volunteers: Absence of Sex Differences , 2004, Anesthesiology.

[9]  J. Lötsch Pharmacokinetic-pharmacodynamic modeling of opioids. , 2005, Journal of pain and symptom management.

[10]  Erik Olofsen,et al.  Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine in Healthy Volunteers , 2006, Anesthesiology.

[11]  K. Samii,et al.  Morphine in Postoperative Patients: Pharmacokinetics and Pharmacodynamics of Metabolites , 2007, Anesthesia and analgesia.

[12]  N. Holford,et al.  Modeling the norketamine metabolite in children and the implications for analgesia , 2007, Paediatric anaesthesia.

[13]  Meindert Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.

[14]  Erik Olofsen,et al.  Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats , 2007, Pharmaceutical Research.

[15]  M. Danhof,et al.  Mechanism‐based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[16]  M. Danhof,et al.  Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine , 2007, Clinical pharmacokinetics.

[17]  Modeling and Simulation to Support Dose Selection and Clinical Development of SC‐75416, a Selective COX‐2 Inhibitor for the Treatment of Acute and Chronic Pain , 2008, Clinical pharmacology and therapeutics.

[18]  N. Holford,et al.  Investigating the pharmacodynamics of ketamine in children , 2007, Paediatric anaesthesia.

[19]  Population Pharmacokinetic–Pharmacodynamic Modeling of Epidural Anesthesia , 2008, Anesthesiology.

[20]  S. Shafer,et al.  Mixed effect modeling in analgesia trials. , 2008, Anesthesia and analgesia.

[21]  A. Dahan,et al.  Morphine‐6‐glucuronide (M6G) for postoperative pain relief , 2008, European journal of pain.

[22]  C. Minto,et al.  Contributions of PK/PD Modeling to Intravenous Anesthesia , 2008, Clinical pharmacology and therapeutics.

[23]  K. Dunn,et al.  Chronic pain reconsidered , 2008, PAIN.

[24]  A. Dahan,et al.  S(+)-ketamine Effect on Experimental Pain and Cardiac Output: A Population Pharmacokinetic-Pharmacodynamic Modeling Study in Healthy Volunteers , 2009, Anesthesiology.

[25]  S. Urien,et al.  Intravenous morphine titration in immediate postoperative pain management: Population kinetic–pharmacodynamic and logistic regression analysis , 2009, PAIN®.

[26]  M. Roberts,et al.  Quantifying Pain Relief Following Administration of a Novel Formulation of Paracetamol (Acetaminophen) , 2010, Journal of clinical pharmacology.

[27]  Susan Okie,et al.  A flood of opioids, a rising tide of deaths. , 2010, The New England journal of medicine.

[28]  A. Dahan,et al.  Ketamine for the treatment of chronic non-cancer pain , 2010, Expert opinion on pharmacotherapy.

[29]  A. Dahan,et al.  Naloxone Reversal of Morphine- and Morphine-6-Glucuronide-induced Respiratory Depression in Healthy Volunteers: A Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling Study , 2010, Anesthesiology.

[30]  A. Dahan,et al.  Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression , 2010, Anesthesiology.

[31]  Kaori Ito,et al.  Exposure‐Response Analyses of the Effects of Pregabalin in Patients With Fibromyalgia Using Daily Pain Scores and Patient Global Impression of Change , 2010, Journal of clinical pharmacology.

[32]  T. Stijnen,et al.  Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies , 2010, PAIN.

[33]  M. Struys,et al.  Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine , 2010, Current opinion in anaesthesiology.

[34]  Stefano Zamuner,et al.  Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  Marieke Niesters,et al.  Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain , 2011, European journal of pain.

[36]  R. Treede,et al.  Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses , 2011, Current medical research and opinion.

[37]  S. Jayawardena,et al.  Modeling the Onset and Offset of Dental Pain Relief by Ibuprofen , 2012, Journal of clinical pharmacology.